Kenneth Research recently added a report on Skin Cancer Diagnostics Industry Market in its database of market research reports which provides its readers an in-depth analysis on the latest trends, growth opportunities and growth drivers that are associated with the growth of the market. The report additionally shares critical insights on the COVID-19 impacts on the Skin Cancer Diagnostics Industry Market along with the compound growth rate (CAGR) of the market for a projected period between 2022 and 2031. The report also includes analysis of the market by utilizing different analytical tools, such as PESTEL analysis and Porter’s five forces analysis. These tools also provide an in-depth analysis on the micro and macro-environmental factors that are associated with the growth of the market during the forecast period.
The U.S. Market recovers fast; In a release on May 4th, 2021, the U.S. Bureau and Economic Analysis and U.S. Census Bureau mention the recovery in the U.S. International trade in March 2021. Exports in the country reached $200 billion, up by $12.4 billion in Feb 2021. Following the continuous incremental trend, imports tallied at $274.5 billion, picked up by $16.4 billion in Feb 2021. However, as COVID19 still haunts the economies across the globe, year-over-year (y-o-y) average exports in the U.S. declined by $7.0 billion from March 2020 till March 2021 whilst imports increased by $20.7 billion during the same time. This definitely shows how the market is trying to recover back and this will have a direct impact on the Healthcare/ICT/Chemical industries, creating a huge demand for Skin Cancer Diagnostics Industry Market products.
The request of this Sample Report here – https://www.kennethresearch.com/sample-request-10151799
“Some of the factors driving market growth include a higher incidence of skin cancer, extensive research and development projects, and increased awareness of skin cancer. Skin cancer is the most common form of cancer. Although most skin cancers are preventable, their incidence is increasing. People can recognize skin changes in the early stages of the disease. Risk factors include sunlight, sun lights and solariums, certain medical conditions or medications. Ultraviolet radiation changes the genetic material (DNA) of cells and is therefore the main cause of skin cancer. According to the American Cancer Society, sun exposure is the most preventable risk factor for all skin cancers.
According to the US Federal Centers for Disease Control and Prevention (CDC), the rate of new melanoma cases in men and women is increasing at an annual rate of 1.7% and 1.4%, respectively. Therefore, the increasing prevalence of skin cancer is increasing the growth of the studied market. However, a common side effect of radiation therapy is skin irritation on the treated body part. Skin reactions can range from mild redness and dryness (similar to sunburn) to severe peeling in some patients.
Most skin reactions to radiation therapy will disappear within a few weeks after the treatment is completed. In some cases, the treated skin will be darker than before and may still be more sensitive to sunlight. About two to three weeks after the first radiation treatment, the redness is obvious, and the irritation is similar to a sunburn. The skin may feel itchy, dry, red, or painful. There are also long-term side effects, such as skin color changes, lung problems, etc., which are the main constraints on the growth of the studied market.
Ultraviolet rays are a major carcinogen, which can cause mutations caused by ultraviolet rays, loss of tumor suppressor gene activity, overexpression of keratinocyte oncogenes, and stimulate the development of skin malignant tumors. The skin cancer diagnosis and treatment market includes various diagnosis and treatment related to skin cancer.
Main market trends:
Non-melanoma is expected to occupy a significant market share in cancer types. According to ASCO (American Society of Clinical Oncology) estimates, more than 3 million people in the United States are diagnosed with skin non-melanoma cancer each year.
Access Full Report here – https://www.kennethresearch.com/report-details/skin-cancer-diagnostics-industry-market/10151799
Basal cell carcinoma is more common than squamous Cell carcinoma is more common. About 80% of non-melanoma skin cancers are basal cell carcinomas. Similarly, CCS (Canadian Cancer Society) pointed out that non-melanoma skin cancer is the most common cancer diagnosed in Canadians. It accounts for at least 40% of all new cancer cases in Canada. The National Institutes of Health stated that in 2017, approximately 948 people in Japan died of non-melanoma skin cancer. Similarly, Australia also faces the burden of death caused by non-melanoma skin cancer. The Cancer Commission stated that between 2016-2027, approximately 679 people in Australia died from this cancer. In addition, the increasing burden of melanoma skin cancer is also expected to drive the market during the forecast period.
North America dominates the market and is expected to do so during the forecast period:
North America is expected to dominate the market during the forecast period. According to the American Academy of Dermatology, skin cancer is the most common cancer in the United States. Most cases of melanoma are the deadliest type of skin cancer and are caused by exposure to ultraviolet (UV) light. It is estimated that approximately 9,500 people in the United States are diagnosed with skin cancer every day. Therefore, the rising incidence of skin cancer in this region is an important factor driving the growth of the studied market. In addition, the latest advances in skin cancer treatment including photodynamic therapy (PDT) have been widely used to treat non-melanoma skin malignancies, thereby driving the growth of the research market during the prognosis period.
The global skin cancer diagnosis and treatment market is highly competitive and consists of several major players. Companies such as Amgen, Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Sun Pharmaceutical Industries Ltd. have a considerable share of the cancer treatment market. skin. .
Sun Pharmaceutical Industries Ltd.
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd
Merck & Co., Inc.
Sun Pharmaceutical Industries Ltd.”
Download Sample PDF of this Report: – https://www.kennethresearch.com/sample-request-10151799
Kenneth Research provides scheduled syndicated reports that help industry professionals and organizations decipher market trends to take significant decisions and plan strategies. We cater to a wide range of industries including healthcare & pharmaceuticals, ICT & telecom, automotive & transportation, energy & power, chemicals, FMCG & food, aerospace & defense, among others. Our research team ensures to track and analyze the industry on a regular basis to offer strategic business consultancy services on a global level. We, at Kenneth Research, are adept at capturing descriptive insights on crucial topics to help our clients make their informed decisions.
Name: Kenneth research
Phone: +1 313 462 0609
Peptide Based Infection Therapeutics Market
Peptide Based Gastrointestinal Disorders Therapeutics Market
Peptide Based Cardiovascular Therapeutics Market
Peptide Based Cancer Therapeutics Market
OTC Herbal and Traditional Medicines Market